OSLO, Norway, April 28, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the 18-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin® in patients with...
Read More Details
Finally We wish PressBee provided you with enough information of ( Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression )
Also on site :
- Legendary Rocker, 84, Says He Still Feels 24
- Tesla driver, 22, accused of ramming motorcyclist from Chula Vista, killing him
- Rock Legend, 76, to Be Inducted Into 2025 Radio Hall of Fame